The intracrinology of breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 145, Issue , 2015, Pages 172-178

  McNamara, Keely May ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; DHEA; Intracrinology

Indexed keywords

CYTOCHROME P450; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; STEROID; ANDROGEN; AROMATASE; ESTROGEN;

BREAST CANCER; BREAST CARCINOMA; ENDOCRINOLOGY; HORMONAL REGULATION; HUMAN; INTRACRINOLOGY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; STEROIDOGENESIS; STROMA; BLOOD; BREAST; BREAST TUMOR; COMPLICATION; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; OBESITY; PATHOLOGY; RISK FACTOR;

ANDROGENS; AROMATASE; BREAST; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OBESITY; RISK FACTORS; STEROIDS;

EID: 84915752920     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.04.004     Document Type: Review

References (95)

1. R.R. Love, and J. Philips Oophorectomy for breast cancer: history revisited J. Natl. Cancer Inst. 94 19 2002 1433 1434
2. F. Labrie Intracrinol. Mol. Cell Endocrinol. 78 3 1991 C113 C118
3. B. Wang Does the increase of endogenous steroid hormone levels also affect breast cancer risk in Chinese women? A case-control study in Chongqing: China Int J Cancer 124 8 2009 1892 1899
4. A.H. Eliassen Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women J. Natl. Cancer Inst. 98 19 2006 1406 1415
5. R. Kaaks Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) J. Natl. Cancer Inst. 97 10 2005 755 765
6. A. Zeleniuch-Jacquotte Premenopausal serum androgens and breast cancer risk: a nested case-control study Breast Cancer Res. 14 1 2012 R32
7. H. Yu Plasma sex steroid hormones and breast cancer risk in Chinese women Int. J. Cancer 105 1 2003 92 97
8. S.R. Sturgeon Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA) Cancer Causes Control 15 1 2004 45 53
9. J.F.et al. Dorgan Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk Breast Cancer Res. 12 6 2010 R98
10. A. Micheli Endogenous sex hormones and subsequent breast cancer in premenopausal women Int. J. Cancer 112 2 2004 312 318
11. H.V. Thomas A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey Br. J. Cancer 75 7 1997 1075 1079
12. H. Sasano Intracrinology of estrogens and androgens in breast carcinoma J. Steroid Biochem. Mol. Biol. 108 3-5 2008 181 185
13. H. Sasano In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology Pathol. Int. 59 11 2009 777 789
14. Y. Miki The advantages of co-culture over mono cell culture in simulating in vivo environment J. Steroid Biochem. Mol. Biol. 131 3-5 2012 68 75
15. J. Zhou Interactions between prostaglandin E(2): liver receptor homologue-1, and aromatase in breast cancer Cancer Res. 65 2 2005 657 663
16. H. Sasano Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders Hum. Pathol. 25 5 1994 530 535
17. F. Labrie Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endocr. Rev. 24 2 2003 152 182
18. T. Suzuki Steroid sulfatase and estrogen sulfotransferase in human carcinomas Mol. Cell. Endocrinol. 340 2 2011 148 153
19. N. Honma Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3beta, 17beta-diol Cancer Sci. 102 10 2011 1848 1854
20. R. Gunasegaram Expression of 3beta-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro Breast Cancer Res. Treat. 50 2 1998 117 123
21. G. Pelletier Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland J. Mol. Endocrinol. 26 1 2001 11 19
22. S. Nagasaki 17beta-hydroxysteroid dehydrogenases in human breast cancer Ann. N.Y. Acad. Sci. 1155 2009 25 32
23. T. Suzuki 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters Br. J. Cancer 82 3 2000 518 523
24. H. Sasano Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma J. Clin. Endocrinol. Metab. 81 11 1996 4042 4046
25. T. Suzuki 5Alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions J. Clin. Endocrinol. Metab. 86 5 2001 2250 2257
26. K.M. McNamara Androgenic pathways in the progression of triple negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes Breast Cancer Res. Treat. 2014 10.1007/s10549-014-2942-6 (in press)
27. Y. Shibahara Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer Hum. Pathol. 44 10 2013 2338 2345
28. T.E. Hickey Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol. Endocrinol. 26 8 2012 1252 1267
29. K. McNamara Androgenic pathway in triple negative invasive ductal tumours: its correlation with tumour cell proliferation Cancer Sci. 104 5 2013 639 646
30. N. Chanplakorn Increased 5alpha-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation Horm. Cancer 2 1 2011 73 81
31. T. Suzuki 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production Int. J. Cancer 120 2 2007 285 291
32. R. Shibuya Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast Endocr. Relat. Cancer 15 1 2008 113 124
33. S. Kasashima Expression of 5alpha-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness Histopathology 60 6B 2012 E51 E57
34. R.J. Santen History of aromatase: saga of an important biological mediator and therapeutic target Endocr. Rev. 30 4 2009 343 375
35. W.R. Miller, T.J. Anderson, and W.J. Jack Relationship between tumour aromatase activity: tumour characteristics and response to therapy J. Steroid Biochem. Mol. Biol. 37 6 1990 1055 1059
36. W.R. Miller Aromatase activity in breast tissue J. Steroid Biochem. Mol. Biol. 39 5B 1991 783 790
37. M.C. Silva Intratumoral aromatase as a prognostic factor in human breast carcinoma Cancer Res. 49 10 1989 2588 2591
38. A. Lipton Prognostic value of breast cancer aromatase Cancer 70 7 1992 1951 1955
39. Y. Shibahara Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer Pathol. Int. 63 1 2013 20 28
40. K.M. McNamara Phase Two Steroid Metabolism and Its Roles in Breast and Prostate Cancer Patients Front. Endocrinol. (Lausanne) 4 2013 116
41. T. Suzuki Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma Cancer Res. 63 11 2003 2762 2770
42. G. Hudelist Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer J. Cancer Res. Clin. Oncol. 134 1 2008 67 73
43. M. Suzuki Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients J. Steroid Biochem. Mol. Biol. 113 3-5 2009 195 201
44. Z. Weihua An endocrine pathway in the prostate: ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth Proc. Nat. Acad. Sci. U.S.A. 99 21 2002 13589 13594
45. T. Hanamura Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers Breast Cancer Res. Treat. 143 1 2013 69 80
46. S.R. Aspinall The proliferative effects of 5-androstene-3 beta,17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines J. Steroid Biochem. Mol. Biol. 88 1 2004 37 51
47. S.J. Santner, P.D. Feil, and R.J. Santen In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway J. Clin. Endocrinol. Metab. 59 1 1984 29 33
48. N. Chanplakorn Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients Breast Cancer Res. Treat. 120 3 2010 639 648
49. E.R. Nelson 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology Science 342 6162 2013 1094 1098
50. J.P. Wiebe Progesterone metabolites in breast cancer Endocr. Relat. Cancer 13 3 2006 717 738
51. J.P. Wiebe, and M.J. Lewis Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells BMC Cancer 3 2003 9
52. M.J. Lewis, J.P. Wiebe, and J.G. Heathcote Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma BMC Cancer 4 2004 27
53. M.E. Hammond American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch. Pathol. Lab. Med. 134 7 2010 e48 e72
54. P. Feherty, G. Farrer-Brown, and A.E. Kellie Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay Br. J. Cancer 25 4 1971 697 710
55. A. Goldhirsch Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann. Oncol. 22 8 2011 1736 1747
56. T. Sorlie Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Nat. Acad. Sci. U.S.A. 98 19 2001 10869 10874
57. P. Farmer Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 29 2005 4660 4671
58. J.P. Crowe Estrogen receptor status as a prognostic indicator for stage I breast cancer patients Breast Cancer Res. Treat. 2 2 1982 171 176
59. S.L. Kong Cellular reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3 to a ligand-inducible growth state Mol. Syst. Biol. 7 2011 526
60. I. Wolf FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer Int. J. Cancer 120 5 2007 1013 1022
61. G.M. Bernardo FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis Development 137 12 2010 2045 2054
62. H.E. Gulbahce Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors Hum. Pathol. 44 11 2013 2427 2431
63. C.I. Li, J.R. Daling, and K.E. Malone Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998 J. Clin. Oncol. 21 1 2003 28 34
64. X. Cui Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J. Clin. Oncol. 23 30 2005 7721 7735
65. G. Arpino Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance J. Natl. Cancer Inst. 97 17 2005 1254 1261
66. J. Carroll Understanding estrogen receptor transcription in breast cancer 2013 San Antonio Breast Cancer Symposium San Antonio, TX
67. J.P. Garay, and B.H. Park Androgen receptor as a targeted therapy for breast cancer Am. J. Cancer Res. 2 4 2012 434 445
68. B.D. Lehmann Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J. Clin. Invest. 121 7 2011 2750 2767
69. K.M. McNamara Androgen receptor in triple negative breast cancer J. Steroid Biochem. Mol. Biol. 133 2013 66 76
70. F. De Amicis Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells Breast Cancer Res. Treat. 121 1 2010 1 11
71. M. Ni Targeting androgen receptor in estrogen receptor-negative breast cancer Cancer Cell 20 1 2011 119 131
72. M. Ni Amplitude modulation of androgen signaling by c-MYC Genes Dev. 27 7 2013 734 748
73. Y. Wang Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers Oncogene 30 42 2011 4327 4338
74. Y. Wang Androgen receptor-induced tumor suppressor: KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas Hum. Mol. Genet. 22 11 2013 2263 2272
75. G.A. Scobie Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants Steroids 67 12 2002 985 992
76. D. Tong Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines Breast Cancer Res. Treat. 71 3 2002 249 255
77. N. Honma Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy J. Clin. Oncol. 26 22 2008 3727 3734
78. M.C. Byrns, and T.M. Penning Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs Chem. Biol. Interact. 178 1-3 2009 221 227
79. G. Bianchini Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers J. Clin. Oncol. 28 28 2010 4316 4323
80. Y. Miki, T. Suzuki, and H. Sasano Controversies of aromatase localization in human breast cancer - stromal versus parenchymal cells J. Steroid Biochem. Mol. Biol. 106 1-5 2007 97 101
81. N.U. Samarajeewa HIF-1alpha stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma Breast Cancer Res. 15 2 2013 R30
82. K.C. Knower Distinct nuclear receptor expression in stroma adjacent to breast tumors Breast Cancer Res. Treat. 142 1 2013 211 223
83. H. Sasano New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase Ann. N.Y. Acad. Sci. 1155 2009 76 79
84. T. Suzuki Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma J. Steroid Biochem. Mol. Biol. 86 3-5 2003 449 454
85. T. Suzuki Analysis for localization of steroid sulfatase in human tissues Methods Enzymol. 400 2005 303 316
86. M. Poutanen Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue Int. J. Cancer 50 3 1992 386 390
87. M. Lanzino DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation Cell Death Dis. 4 2013 e724
88. S. Gingras, S. Cote, and J. Simard Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells Mol. Endocrinol. 14 2 2000 229 240
89. S. Gingras Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13 Mol. Endocrinol. 13 1 1999 66 81
90. E.F. Adams Paracrine influence of human breast stromal fibroblasts on breast epithelial cells: secretion of a polypeptide which stimulates reductive 17 beta-oestradiol dehydrogenase activity Int. J. Cancer 42 1 1988 119 122
91. F. Labrie Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease J. Mol. Endocrinol. 25 1 2000 1 16
92. B. Han Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters J. Steroid Biochem. Mol. Biol. 112 4-5 2008 194 200
93. Y. Miyoshi Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers Int. J. Cancer 94 5 2001 685 689
94. A. Brodie, B. Long, and Q. Lu Aromatase expression in the human breast Breast Cancer Res. Treat. 49 Suppl 1 1998 S85 S91 discussion S109-19
95. P. Roger Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors Cancer Res. 61 6 2001 2537 2541